Shire 2Q Revenues: $3.9 billion (+5%) 2Q Earnings: $616 million (+156%) YTD Revenues: $7.7 billion (+5%) YTD Earnings: $1.2 billion (+96%) Comments: Immunology sales were $1.1 billion in the quarter, up 13% driven by Immunoglobulin therapies. Hematology sales were down 1% to $951.0 million. Neuroscience sales were up 9% to $693.7 million driven by Vyvanse and Adderall XR. Internal medicine revenues were up 61% to $232.9 million driven by Gattex and Natpara, up 77% and 88% respectively. Esta...